Eravacycline in allogeneic stem cell transplant recipients: A real-world study of drug-drug interactions with cyclosporine/tacrolimus and anti-infective efficacy (ASH 2025) - Dec 5, 2025 - "Eravacycline, a novel synthetic tetracycline, shares the Cytochrome P450 3A4 (CYP3A4) metabolic pathway with CNIs, yet comprehensive data on their potential pharmacokinetic interactions are scarce...Subgroup analysis revealed that when co-administered azoles and letermovir, no significant changes in C/D ratio were observed between pre-treatment and during treatment both in cyclosporine group (n=18) and tacrolimus group (n=7)... This study presented the first clinical evidence of drug-drug interaction between eravacycline with CNIs in allo-HSCT, characterized by increased CNI exposure during eravacycline administration and delayed post-cessation exposure elevation. Intensified CNI monitoring and stepwise dose adjustments are recommended throughout and after eravacycline therapy."
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Transplantation • CYP3A4
|
|
Jieya Luo; Xinhui Zheng; Xin Chen; Erlie Jiang
|